Growth Hormone Deficiency Clinical Trial
Official title:
A Randomised, Open-label, Parallel-group, Multi-centre Trial to Compare the Efficacy and Safety for 12 Months of Zomacton to Genotropin in Children With Idiopathic Growth Hormone Deficiency
This trial is set up to compare Zomacton to Genotropin for the treatment of growth hormone deficiency in children. The children will be treated for 1 year. Half of the patients will be treated with Genotropin and half with Zomacton. During this time they will be dosed every day by themselves or their parents at home in the evening. There will be 138 patients in the trial from age 3 to age 11. The patients cannot have been treated before with growth hormone and the patients must have a proven growth hormone deficiency, this will be shown by a specific test that will be performed before the trial in the local clinic and once during the trial. During the time of the treatment the patients will come to visit the clinic every 3 months. At these visits their heights will be measured, blood samples will be taken, physical examinations will be performed and questions about their health will be asked. At 2 times in the trial they will have a hand x-ray taken to measure the bone age. At the end of the trial the patients will stop the treatment and continue on one of the marketed products available to treat growth hormone deficiency.
Status | Completed |
Enrollment | 165 |
Est. completion date | July 2012 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 3 Years to 11 Years |
Eligibility |
Inclusion Criteria: 1. Signed informed consent 2. Children aged =3yrs old and not above 10 yrs for girls or 11 yrs for boys 3. Idiopathic growth hormone deficiency confirmed during the pre-screening period by a standard GH stimulation test (defined as peak level of <10ng/ml pr lower if so required by the country specific board(s) 4. Height SDS <-2 SD of ref value for CA 5. Height velocity SDSCA = 0 SD of ref value for at lease 6 months prior to pre-screening 6. Height recorded for at least 6 months but not more than 18 months of pre-screening 7. The difference between CA-BA= 1 8. A positive locally performed GH stimulation test (defined as a peak plasma level of<9ng/ml or lower if so required by the country specific board(s)) prior to the pre-screening Exclusion Criteria: 1. BA above 9 yrs for girls and 10 yrs for boys 2. Puberty Tanner stage >1 3. Weight <12 Kg at screening 4. Any prior treatment with GH 5. Closed epiphysis 6. Any diagnosed or suspected syndrome (e.g. Silver -Russell, Turner's or seckel syndrome) which possibly could affect growth 7. Any other diagnosed or suspected endocrine or metabolic disorder 8. Any diagnosed or suspected sever chronic disease 9. Clinical signs of dysmorphic features, malformations or mental retardations 10. Growth failure due to other disorders 11. Previous or present use of drugs that could interfere with GH treatment (e.g. steroids) 12. Diagnosed malignant disease 13. Any abnormal CS lab results that requires further investigation 14. Receipt of an investigational drug within the last 28 days preceding screening or longer if considered possible to influence the outcome of the current trial 15. Any knowledge of hypersensitivity to somatropin or any of the excipients of Zomacton or Genotropin |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Hungary | Semmelweiss University, 1st dept of paediatrics | Budapest | |
Hungary | Szent Janos Kh Budai | Budapest | |
Hungary | Petz Country Teaching Hospital | Gyor | |
Hungary | University of Szeged | Szeged | |
Hungary | Markusovszkty Teaching Hospital | Szombathely | |
India | Associates in Clinical Endocrinology Education and Research (ACEER) | Chennai | |
India | Apollo Hospitals | Hyderabad | |
India | TOTALL Diabetes Hormone Institute | Indore | |
India | KEM Hospital | Mumbai | |
India | Prince Aly Khan Hospital | Mumbai | |
India | Endocare Clinic | Nasik | |
India | Jehangir Clinical Development Centre Pvt. Ltd., Jehangir Hospital | Pune | |
India | Health & Research Centre | Trivandrum | |
Israel | Haemek Medical Center | Afula | |
Israel | Soroka University Medical Center | Beer Sheva | |
Israel | Western Galilee Medical Center | Nahariya | |
Israel | Schneider Children's Medical Center of Israel | Petach Tikva | |
Israel | Edmond and Lily Safra Children's hospital - The Chaim Sheba Medical Center | Ramat Gan | |
Israel | Kaplan Medical Center | Rehovot | |
Israel | Dana Children's Hospital - Tel-Aviv Sourasky Medical Center | Tel Aviv | |
Poland | Wojewódzki Szpital Dzieciecy im. J.Brudzinskiego w Bydgoszczy | Bydgoszcz | |
Poland | Uniwersyteckie Centrum Kliniczne, Gdansk | Gdansk | |
Poland | Uniwersytecki Szpital Dzieciecy w Krakowie | Krakow | |
Poland | SPSK nr.1 im. Prof. T. Sokolowskiego PAM Szczecin | Szczecin | |
Romania | Societatea Civila Medicala "Dr. Paveliu" | Bucuresti | |
Romania | Spitalul Clinic Municipal "Filantropia" | Craiova | |
Romania | Spitalul Clinic Judetean de Urgenta "Sf. Spiridon" | Iasi | |
Romania | Spitalul Clinic Judetean Mures | Targu Mures | |
Romania | Paediatric Endocrinology/Medicali's SRL | Timisoara | |
Romania | Spitalul Clinic pentru Copii Louis Turcanu | Timisoara | |
Russian Federation | State Educational Institution of Higher Professional Education "Kazan State Medical University of ROSZDRAV | Kazan | |
Russian Federation | Federal State Institution | Moscow | |
Russian Federation | Russian Medical Academy of Post-graduate Education | Moscow | |
Russian Federation | Saint-Petersburg State Health Care Institution | Saint Petersburg | |
Russian Federation | State Educational Institution for Higher Professional Education | Saratov | |
Russian Federation | State Educational Institution of Higher Professional Education "Siberian State Medical University of ROSZDRAV | Tomsk | |
Ukraine | Donetsk Regional Clinical Children's Hospital | Donetsk | |
Ukraine | Ivano-Frankivsk Regional Children Clinical Hospital | Ivano-Frankivsk | |
Ukraine | Kharkiv Regional Clinical Children's Hospital | Kharkiv | |
Ukraine | Institute of Endocrinology and Metabolism | Kiev | |
Ukraine | Ukrainian Children's Specialized Clinical Hospital | Kiev | |
Ukraine | Odessa National Medical University - (Located at Odessa Region Children's Clinical Hospital) | Odessa | |
Ukraine | Zaporizhzhya Regional Paediatric Hospital | Zaporizhya |
Lead Sponsor | Collaborator |
---|---|
Ferring Pharmaceuticals |
Hungary, India, Israel, Poland, Romania, Russian Federation, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Height Velocity | 12 months | No | |
Secondary | Height SDS | 12 months | No | |
Secondary | Height velocity SDS | 12 months | No | |
Secondary | Change in IGF-1 and IGFBP-3 | 12 months | No | |
Secondary | BA (Bone Age) | 12 months | No | |
Secondary | Anti-hGH AB | 12 months | Yes | |
Secondary | AE and tolerability | 12 months | Yes | |
Secondary | CS Changes in safety lab, physical examination and vital signs | 12 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02243852 -
Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)
|
N/A | |
Completed |
NCT01440686 -
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00990340 -
Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method
|
Phase 4 | |
Completed |
NCT00235599 -
The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.
|
N/A | |
Completed |
NCT00149708 -
Consequence of Lifetime Isolated Growth Hormone Deficiency
|
N/A | |
Completed |
NCT00459940 -
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients
|
N/A | |
Completed |
NCT01157793 -
A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood
|
Phase 4 | |
Completed |
NCT00004365 -
Study of Pituitary Size and Function in Familial Dwarfism of Sindh
|
N/A | |
Recruiting |
NCT00227253 -
Chromosome 18 Clinical Research Center
|
||
Recruiting |
NCT04121780 -
Growth Hormone Replacement Therapy for Retried Professional Football Players
|
Phase 2 | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Completed |
NCT01090778 -
Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)
|
Phase 2 | |
Completed |
NCT01062529 -
Peripheral Metabolic Effects of Somatostatin
|
N/A | |
Completed |
NCT00965484 -
Genotropin Study Assessing Use of Injection Pen
|
Phase 3 | |
Completed |
NCT00616278 -
National Cooperative Growth Study in CKD
|
N/A | |
Completed |
NCT02693522 -
Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency
|
Phase 3 | |
Recruiting |
NCT02908958 -
Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency
|
Phase 4 | |
Terminated |
NCT01243892 -
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
|
N/A | |
Withdrawn |
NCT00638287 -
Inter-Assay Growth Hormone and IGF-I Variability
|
N/A | |
Completed |
NCT00929799 -
Growth Hormone and Glucose Metabolism
|
Phase 4 |